Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04032847 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | terminated | Phase 1 / Phase 2 | 27 | Achilles Therapeutics UK LimitedINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT00503971 | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. | terminated | Phase 1 / Phase 2 | 33 | Spanish Lung Cancer GroupOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT00979576 | BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03496766 | Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | terminated | Phase 2 | 9 | Spanish Lung Cancer GroupOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma | terminated | Phase 2 | 68 | Emory UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | terminated | Phase 3 | 12 | Boehringer IngelheimINDUSTRY | 3 | Feb 13, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | terminated | Phase 1 | 43 | Seagen Inc.INDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT05407038 | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue | terminated | N/A | 7 | Mayo ClinicOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | terminated | Phase 1 | 13 | Biomea Fusion Inc.INDUSTRY | 2 | Feb 7, 2025 | clinicaltrials |
| NCT04474613 | Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites | terminated | N/A | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | terminated | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT02592967 | Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer | terminated | Phase 1 | 18 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | terminated | Phase 3 | 9 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 3, 2025 | clinicaltrials |
| NCT03705403 | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study(IMMUNOSABR2) | terminated | Phase 2 | 88 | Maastricht University Medical CenterOTHER | 6 | Jan 30, 2025 | clinicaltrials |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | terminated | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Jan 28, 2025 | clinicaltrials |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | terminated | Phase 1 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04856176 | A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | terminated | Phase 2 | 5 | Tufts Medical CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | terminated | Phase 2 | 2 | Brian Henick, MDOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04364048 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | Rachel SanbornOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | terminated | Phase 1 | 7 | Mirati Therapeutics Inc.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | terminated | Phase 1 | 21 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT04515979 | Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects | terminated | Phase 2 | 11 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | terminated | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05304390 | A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle | terminated | N/A | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT02495233 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | terminated | Phase 1 / Phase 2 | 10 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04951115 | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02500927 | A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations | terminated | Phase 2 | 31 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03082300 | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 | 3 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03166631 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | terminated | Phase 1 | 62 | Boehringer IngelheimINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT04287894 | Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment(Induction) | terminated | Phase 1 | 18 | The Netherlands Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | terminated | Phase 1 | 64 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT04791215 | Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab | terminated | — | 10 | Columbia UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT01088906 | Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC(Phalcis) | terminated | Phase 2 | 57 | Spanish Lung Cancer GroupOTHER | 1 | Oct 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2025source: clinicaltrials